 |
Prospector
Profile
114-06
|
| |
| Intraop Medical Corp. |
NAICS |
339100 |
| 570 Del Rey Avenue
Sunnyvale, CA 94086 |
Description |
Medical Equipment Mfg. |
| (408) 636-1020 |
Employees |
24 |
| http://www.intraopmedical.com/ |
Revenue |
(mil) |
3.9470 |
| |
Income |
(mil) |
-6.0260 |
| |
Assets |
(mil) |
8.5550 |
| |
Liability |
(mil) |
10.9420 |
| |
(for the year ended 2007-09-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
PMB Helin Donovan LLP raised substantial doubt about the ability of Intraop Medical Corp. to continue as a going concern after auditing its financial statements for the year ended September 30, 2007. The auditor notes that the Company has incurred substantial net losses and incurred substantial monetary liabilities in excess of monetary assets over the past several years. The Company had a net loss of $6,026,740 on revenues of $3,947,657 for the year ended September 30, 2007, compared to a net loss of $7,160,101 on revenues of $5,982,954 for the year ended September 30, 2006. The Company's balance sheet at September 30, 2007, showed an accumulated deficit of $34,041,658, stockholders' deficit of $2,387,126 and working capital deficit of $3,308,014.
|
| |
|
Intellectual Property:
A basic systems patent for Mobetron was granted on June 14, 1994. A second systems patent which extended the claims of the first patent to the technology used in conventional accelerators was granted on May 23, 1995. These two patents protect the use of a linear accelerator in a mobile, self-shielded application. In 1997, a patent protecting the electron accelerator technology used in Mobetron was granted, and in 2000, a patent on the unique alignment system used to orient Mobetron to the tumor prior to irradiation was also granted. Mobetron also has international patent protection in Japan, key European countries, and Russia. The Company also holds trademarks for "Mobetron" and "Intraop Medical." [SEC Filing 10-KSB 12-14-07]
|
| |
|
Description:
The Company engages in the development, manufacture, marketing, distribution, and servicing of its Mobetron system. The Mobetron system is a mobile electron-beam cancer treatment system designed for use in intraoperative electron-beam radiation therapy.
|
| |
|
Officers:
Oliver Janssen (Chair); John Powers (Pres., CEO & Dir.); Donald A. Goer Ph.D. (Chief Scientist); Richard Belford (VP); Scott Mestman (VP); Richard Simon (VP); Howard Solovei (Sec. & CFO); Michael Friebe Ph.D. (Dir.); Keith Jacobsen (Dir.); Stephen L. Kessler (Dir.); Greg Koonsman (Dir.); Rawleigh Ralls (Dir.)
|
| |
|
Auditor:
PMB Helin Donovan LLP
|
| |
|
Securities:
Common Stock-Symbol IOPM.OB; OTC BB;
322,985,524 common shares outstanding as of November 30, 2007.
|
| |
| |
| |
| return to main page |
|
|
